Last reviewed · How we verify
NCT07278011
Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa
trial in Hidradenitis Suppurativa (HS) in 30 participants. Completed in 21 November 2025.
25 September 2025
Quick facts
| Lead sponsor | Trakya University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 6 January 2025 |
| Primary completion | 25 September 2025 |
| Estimated completion | 21 November 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Hidradenitis Suppurativa (HS) — all drugs for Hidradenitis Suppurativa (HS) →
- Skin Inflammation — all drugs for Skin Inflammation →
Sponsor
Trakya University
Who can join
18 and older, any sex, with Hidradenitis Suppurativa (HS) or Skin Inflammation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational translational study aims to investigate gene and protein expression in lesional and perilesional skin of patients with Hidradenitis Suppurativa (HS) compared to controls. Skin biopsies were collected from 15 HS patients and 15 age- and sex-matched healthy controls. Gene expression of 15 selected proteins was analyzed using qRT-PCR, while protein levels of 4 targets were assessed by Western blot. The study seeks to identify molecular pathways involved in HS pathogenesis and potential biomarkers for disease severity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07278011
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hidradenitis Suppurativa (HS)
Currently open trials in the same condition.
- NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
- NCT07287644 — A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa · Phase 2, PHASE3 · recruiting
- NCT07155239 — 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) · Phase 1 · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
- NCT07109765 — Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa · recruiting
Other Trakya University trials
Trials by the same sponsor.
- NCT07443735 — Pinwheel and Bubble Blowing for Pain and Emotional Responses in Children · NA · not yet recruiting
- NCT07464795 — The Effects of Kinesio Taping on Heel-Rise Endurance and Gastrocnemius Muscle Oxygenation in Healthy Young Adults · NA · not yet recruiting
- NCT07421687 — 3D Volumetric Plaque Assessment on Teeth, Composite Restorations, and Ceramic Veneers Using an Intraoral Scanner · not yet recruiting
- NCT07481188 — Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery · recruiting
- NCT07349056 — Early Effects of Orthognathic Surgery on Periodontal Phenotype: A 6-Month Prospective Clinical and Radiographic Evaluati · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07278011 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Trakya University
- Last refreshed: 11 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07278011.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing